BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 31281427)

  • 1. Chemotherapy and anti-HER2 therapy in metastatic breast cancer in pregnancy followed by surgical treatment.
    Berwart J; Peccatori FA
    Ecancermedicalscience; 2019; 13():930. PubMed ID: 31281427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overview of resistance to systemic therapy in patients with breast cancer.
    Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
    Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Breast cancer under age 40: a different approach.
    Ribnikar D; Ribeiro JM; Pinto D; Sousa B; Pinto AC; Gomes E; Moser EC; Cardoso MJ; Cardoso F
    Curr Treat Options Oncol; 2015 Apr; 16(4):16. PubMed ID: 25796377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Examination of a paradox: recurrent metastatic breast cancer incidence decline without improved distant disease survival: 1990-2011.
    Malmgren J; Hurlbert M; Atwood M; Kaplan HG
    Breast Cancer Res Treat; 2019 Apr; 174(2):505-514. PubMed ID: 30560462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Role of clustered HER2/neu amplification as a marker for a special sensitivity to neoadjuvant anti-HER2 therapy with trastuzumab in patients with stage II-III breast cancer].
    Kolyadina IV; Zavalishina LE; Ganshina IP; Andreeva YY; Frank GA; Gordeeva OO; Zhukova LG; Meshcheryakov AA; Savelov NA; Tuzova EA; Morozov DA; Poddubnaya IV
    Arkh Patol; 2019; 81(6):56-62. PubMed ID: 31851193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized controlled trial comparing primary tumour resection plus systemic therapy with systemic therapy alone in metastatic breast cancer (PRIM-BC): Japan Clinical Oncology Group Study JCOG1017.
    Shien T; Nakamura K; Shibata T; Kinoshita T; Aogi K; Fujisawa T; Masuda N; Inoue K; Fukuda H; Iwata H
    Jpn J Clin Oncol; 2012 Oct; 42(10):970-3. PubMed ID: 22833684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The curability of breast cancer and the treatment of advanced disease.
    Guarneri V; Conte PF
    Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S149-61. PubMed ID: 15107948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abundant tumor infiltrating lymphocytes after primary systemic chemotherapy predicts poor prognosis in estrogen receptor-positive/HER2-negative breast cancers.
    Watanabe T; Hida AI; Inoue N; Imamura M; Fujimoto Y; Akazawa K; Hirota S; Miyoshi Y
    Breast Cancer Res Treat; 2018 Feb; 168(1):135-145. PubMed ID: 29168063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Locally advanced non inflammatory breast cancer treated by combined chemotherapy and preoperative irradiation: updated results in a series of 120 patients].
    Lerouge D; Touboul E; Lefranc JP; Genestie C; Moureau-Zabotto L; Blondon J
    Cancer Radiother; 2004 Jun; 8(3):155-67. PubMed ID: 15217583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic impact of breast cancer subtypes in elderly patients.
    Bergen ES; Tichy C; Berghoff AS; Rudas M; Dubsky P; Bago-Horvath Z; Mader RM; Exner R; Gnant M; Zielinski CC; Steger GG; Preusser M; Bartsch R
    Breast Cancer Res Treat; 2016 May; 157(1):91-9. PubMed ID: 27107570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Breast carcinoma with an Oncotype Dx recurrence score <18: Rate of distant metastases in a large series with clinical follow-up.
    Wen HY; Krystel-Whittemore M; Patil S; Pareja F; Bowser ZL; Dickler MN; Norton L; Morrow M; Hudis CA; Brogi E
    Cancer; 2017 Jan; 123(1):131-137. PubMed ID: 27526056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use and Yield of Baseline Imaging and Laboratory Testing in Stage II Breast Cancer.
    Bychkovsky BL; Guo H; Sutton J; Spring L; Faig J; Dagogo-Jack I; Battelli C; Houlihan MJ; Yeh TC; Come SE; Lin NU
    Oncologist; 2016 Dec; 21(12):1495-1501. PubMed ID: 27551013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surgery of primary tumour has survival benefit in metastatic breast cancer with single-organ metastasis, especially bone.
    Rhu J; Lee SK; Kil WH; Lee JE; Nam SJ
    ANZ J Surg; 2015 Apr; 85(4):240-4. PubMed ID: 25996008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathological and Treatment-Associated Prognostic Factors in Patients with Breast Cancer Leptomeningeal Metastases in Relation to Tumor Biology.
    Griguolo G; Pouderoux S; Dieci MV; Jacot W; Bourgier C; Miglietta F; Firmin N; Conte P; Viala M; Guarneri V; Darlix A
    Oncologist; 2018 Nov; 23(11):1289-1299. PubMed ID: 30120164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ki67 and lymphocytes in the pretherapeutic core biopsy of primary invasive breast cancer: positive markers of therapy response prediction and superior survival.
    Schlotter CM; Tietze L; Vogt U; Heinsen CV; Hahn A
    Horm Mol Biol Clin Investig; 2017 Sep; 32(2):. PubMed ID: 28937963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of breast cancer subtypes on breast cancer specific survival, distant metastases and local relapse rates in conservatively managed early stage breast cancer: a retrospective clinical study.
    Sanpaolo P; Barbieri V; Genovesi D
    Eur J Surg Oncol; 2011 Oct; 37(10):876-82. PubMed ID: 21824742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical outcome in women with HER2-positive de novo or recurring stage IV breast cancer receiving trastuzumab-based therapy.
    Rossi V; Nolè F; Redana S; Adamoli L; Martinello R; Aurilio G; Verri E; Sapino A; Viale G; Aglietta M; Montemurro F
    Breast; 2014 Feb; 23(1):44-9. PubMed ID: 24210572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metastatic breast cancer incidence, site and survival in Australia, 2001-2016: a population-based health record linkage study protocol.
    Lord SJ; Kiely BE; Pearson SA; Daniels B; O'Connell DL; Beith J; Bulsara MK; Houssami N
    BMJ Open; 2019 Feb; 9(2):e026414. PubMed ID: 30709862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association with pregnancy increases the risk of local recurrence but does not impact overall survival in breast cancer: A case-control study of 87 cases.
    Genin AS; De Rycke Y; Stevens D; Donnadieu A; Langer A; Rouzier R; Lerebours F
    Breast; 2016 Dec; 30():222-227. PubMed ID: 26456897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary and secondary distant metastatic breast cancer: two sides of the same coin.
    Güth U; Magaton I; Huang DJ; Fisher R; Schötzau A; Vetter M
    Breast; 2014 Feb; 23(1):26-32. PubMed ID: 24215983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.